[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100591395":3},{"organization":4,"outcomesModule":7,"designInfo":38,"detailedDescription":11,"studyPopulation":41,"armGroups":42,"interventions":60,"overallOfficials":11,"centralContacts":71,"locations":77,"responsibleParty":197,"collaborators":11,"id":199,"slug":200,"hasResults":201,"nctId":202,"briefTitle":203,"officialTitle":203,"acronym":11,"eligibilityCriteria":204,"healthyVolunteers":201,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":11,"studyType":211,"phases":11,"briefSummary":212,"conditions":213,"keywords":11,"overallStatus":80,"whyStopped":11,"lastUpdateSubmitDate":215,"lastUpdatePostDateStruct":216,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":224},{"fullName":5,"class":6},"Xijing Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":19,"otherOutcomes":11},[9,13,15,17],{"measure":10,"description":11,"timeFrame":12},"Multi-gene methylation levels",null,"Group one: Preoperative, 1 week, 1 month, 3 months, 6 months, 1 year, 1.5 years, 2 years, 3 years, 4 years, and 5 years postoperatively.",{"measure":10,"description":11,"timeFrame":14},"Group two: pre-neoadjuvant therapy baseline, 1 week following neoadjuvant therapy, and postoperatively at 1 week, 1 month, 3 months, 6 months, 1 year, 18 months (1.5 years), 2 years, 3 years, 4 years, and 5 years.",{"measure":10,"description":11,"timeFrame":16},"Group three: pre-neoadjuvant therapy baseline, 1 week following neoadjuvant therapy, and post-neoadjuvant therapy at 1 month, 3 months, 6 months, 1 year, 18 months (1.5 years), 2 years, 3 years, 4 years, and 5 years.",{"measure":10,"description":11,"timeFrame":18},"Group four: pre-definitive chemoradiotherapy baseline, and post-definitive chemoradiotherapy at 1 month, 3 months, 6 months, 1 year, 18 months (1.5 years), 2 years, 3 years, 4 years, and 5 years.",[20,23,26,29,30,31,32,33,34,35,36,37],{"measure":21,"description":22,"timeFrame":12},"Tumor Markers (including CEA, AFP, CA125, CA19-9, CA72-4, etc.)","Tumor Markers (including CEA, AFP, CA125, CA19-9, CA72-4, etc.) results will be extracted from historical medical records, with test dates typically ranging from baseline (within 3 months pre-enrollment) to follow-up intervals aligned with standard clinical practice (e.g., every 3-6 months post-treatment). These time points may not synchronize with the methylation assessment schedule.",{"measure":24,"description":25,"timeFrame":12},"Imaging Examinations (including contrast-enhanced CT, PET\u002FCT, ultrasound, X-ray, magnetic resonance imaging, etc.)","Imaging examinations (including contrast-enhanced CT, PET\u002FCT, ultrasound, X-ray, magnetic resonance imaging, etc.) results will be collected from patient records. Imaging time points are determined by clinical needs (e.g., pre-treatment staging, 3-month post-treatment follow-up), with intervals independent of the methylation analysis schedule. The minimum interval between imaging and methylation sampling will be recorded.",{"measure":27,"description":28,"timeFrame":12},"Endoscope","Endoscoping results will be collected from patient records. Imaging time points are determined by clinical needs (e.g., pre-treatment staging, 3-month post-treatment follow-up), with intervals independent of the methylation analysis schedule. The minimum interval between imaging and methylation sampling will be recorded.",{"measure":21,"description":22,"timeFrame":14},{"measure":24,"description":25,"timeFrame":14},{"measure":27,"description":28,"timeFrame":14},{"measure":21,"description":22,"timeFrame":16},{"measure":24,"description":25,"timeFrame":16},{"measure":27,"description":28,"timeFrame":16},{"measure":21,"description":22,"timeFrame":18},{"measure":24,"description":25,"timeFrame":18},{"measure":27,"description":28,"timeFrame":18},{"allocation":11,"interventionModel":11,"interventionModelDescription":11,"primaryPurpose":11,"observationalModel":39,"timePerspective":40,"maskingInfo":11},"COHORT","PROSPECTIVE","Esophageal cancer patients",[43,48,52,56],{"label":44,"type":11,"description":45,"interventionNames":46},"Group one","Esophageal cancer patients undergoing primary surgical treatment",[47],"Other: Multi-gene methylation testing",{"label":49,"type":11,"description":50,"interventionNames":51},"Group two","Esophageal cancer patients undergoing surgery following neoadjuvant therapy",[47],{"label":53,"type":11,"description":54,"interventionNames":55},"Group three","Esophageal cancer patients undergoing active surveillance following neoadjuvant therapy",[47],{"label":57,"type":11,"description":58,"interventionNames":59},"Group four","Esophageal cancer patients undergoing definitive chemoradiotherapy with or without immunotherapy",[47],[61,65,67,69],{"type":6,"name":62,"description":63,"armGroupLabels":64,"otherNames":11},"Multi-gene methylation testing","Undergo multi-gene methylation testing in blood during follow-up",[44],{"type":6,"name":62,"description":63,"armGroupLabels":66,"otherNames":11},[49],{"type":6,"name":62,"description":63,"armGroupLabels":68,"otherNames":11},[53],{"type":6,"name":62,"description":63,"armGroupLabels":70,"otherNames":11},[57],[72],{"name":73,"role":74,"phone":75,"phoneExt":11,"email":76},"Zhongyang Zhang","CONTACT","+86 188 3136 3219","18831363219@163.com",[78,96,111,124,138,150,156,169,183],{"facility":79,"status":80,"city":81,"state":82,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":90,"contacts":91},"Gansu Wuwei Cancer Hospital","RECRUITING","Wuwei","Gansu","China","CN",{"type":86,"coordinates":87},"Point",[88,89],102.63202,37.92672,{"lat":89,"lon":88},[92],{"name":93,"role":74,"phone":94,"phoneExt":11,"email":95},"Sitian Dai","+86 19567636380","dai15075843463@163.com",{"facility":97,"status":98,"city":99,"state":100,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":101,"geoPoint":105,"contacts":106},"Cancer Hospital Affiliated to Shantou University Medical College","NOT_YET_RECRUITING","Shantou","Guangdong",{"type":86,"coordinates":102},[103,104],116.67876,23.35489,{"lat":104,"lon":103},[107],{"name":108,"role":74,"phone":109,"phoneExt":11,"email":110},"Jialu Jiang","+86 18354692937","jiangjialu325@163.com",{"facility":112,"status":80,"city":113,"state":100,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":114,"geoPoint":118,"contacts":119},"Zhaoqing Gaoyao District People's Hospital","Zhaoqing",{"type":86,"coordinates":115},[116,117],112.46091,23.04893,{"lat":117,"lon":116},[120],{"name":121,"role":74,"phone":122,"phoneExt":11,"email":123},"Xianchun Gao","+86 18165302960","gigaoxc@163.com",{"facility":125,"status":80,"city":126,"state":127,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":128,"geoPoint":132,"contacts":133},"Henan Cancer Hospital","Zhengzhou","Henan",{"type":86,"coordinates":129},[130,131],113.64861,34.75778,{"lat":131,"lon":130},[134],{"name":135,"role":74,"phone":136,"phoneExt":11,"email":137},"Abudurousuli Reyila","+86 15254166320","ryldoct@163.com",{"facility":139,"status":98,"city":140,"state":141,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":142,"geoPoint":146,"contacts":147},"Tangdu Hospital","Xi'an","Shaanxi",{"type":86,"coordinates":143},[144,145],108.92861,34.25833,{"lat":145,"lon":144},[148],{"name":149,"role":74,"phone":122,"phoneExt":11,"email":123},"Xianchun Gao, doctor",{"facility":5,"status":80,"city":140,"state":141,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":151,"geoPoint":153,"contacts":154},{"type":86,"coordinates":152},[144,145],{"lat":145,"lon":144},[155],{"name":73,"role":74,"phone":75,"phoneExt":11,"email":76},{"facility":157,"status":98,"city":158,"state":141,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":159,"geoPoint":163,"contacts":164},"The First Affiliated Hospital of Yan'an University","Yan’an",{"type":86,"coordinates":160},[161,162],109.49167,36.59889,{"lat":162,"lon":161},[165],{"name":166,"role":74,"phone":167,"phoneExt":11,"email":168},"Jun Yu","+86 15872427852","drxiaoyu0801@163.com",{"facility":170,"status":98,"city":171,"state":172,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":173,"geoPoint":177,"contacts":178},"The First Affiliated Hospital of Shanxi Medical University","Taiyuan","Shanxi",{"type":86,"coordinates":174},[175,176],112.56028,37.86944,{"lat":176,"lon":175},[179],{"name":180,"role":74,"phone":181,"phoneExt":11,"email":182},"Yan Pan","+86 13484660214","panpan@fmmu.edu.cn",{"facility":184,"status":80,"city":185,"state":186,"zip":11,"country":83,"countryCode":84,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"General Hospital of Western Theater Command, People's Liberation Army (PLA)","Chengdu","Sichuan",{"type":86,"coordinates":188},[189,190],104.06667,30.66667,{"lat":190,"lon":189},[193],{"name":194,"role":74,"phone":195,"phoneExt":11,"email":196},"Rong Zheng","19829758242","zhengrong4956@163.com",{"type":198,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100591395","investigating-multigene-methylation-dynamics-in-treatment-response-surveillance-for-esophageal-carcinoma-100591395",false,"NCT06979869","Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Esophageal Carcinoma","Inclusion Criteria:\n\nAge at initial diagnosis: 18-75 years (inclusive) Confirmed diagnosis: Histologically proven esophageal carcinoma with complete medical records, including (a) definitive pathological diagnosis report, (b) TNM staging per AJCC 8th edition criteria Cancer history: No prior malignancies at other anatomical sites (excluding cured non-melanoma skin cancers\u002Fcarcinoma in situ) Metastasis status: Radiologically confirmed absence of distant metastases in liver, lungs, or other organs via contrast-enhanced CT\u002FMRI and whole-body bone scan within 4 weeks before enrollment Treatment-naïve status: No previous exposure to (i) esophageal resection surgery, (ii) systemic chemotherapy, (iii) thoracic radiation therapy (\\>10 Gy), or (iv) PD-1\u002FPD-L1 immune checkpoint inhibitors\n\nExclusion Criteria:\n\nLife expectancy \\\u003C6 months (as assessed by ECOG score ≥4 or Palliative Performance Scale ≤30%) Cognitive\u002Fpsychiatric conditions: a. Legally incapacitated individuals without legal guardians, b. Active psychotic disorders (e.g., schizophrenia, bipolar disorder) or dementia (MMSE score \\\u003C24) Investigator-determined exclusions","ALL","18 Years","75 Years",{"count":209,"type":210},300,"ESTIMATED","OBSERVATIONAL","The primary objective is to determine whether pretreatment-to-posttreatment changes in circulating multigene methylation levels correlate with objective response rates (ORR) assessed by contrast-enhanced CT\u002FMRI and levels of serum tumor markers. Secondary endpoints include: (a) time-dependent association between methylation fluctuation patterns and progression-free survival (PFS), (b) comparative diagnostic accuracy of methylation indices versus conventional biomarkers, and (c) feasibility of using methylation thresholds to guide adaptive therapy modification.",[214],"Esophageal Cancer","2026-08-25",{"date":217,"type":218},"2026-08-27","ACTUAL",{"date":220,"type":218},"2025-05-26",{"date":222,"type":210},"2030-03-01",{"name":5,"class":6},9]